KDEV Karolinska Development AB

Karolinska Development changes date for the Annual General Meeting

Karolinska Development changes date for the Annual General Meeting

STOCKHOLM – March 16, 2020. Due to COVID-19, Karolinska Development has postponed the date for the Annual General Meeting from May 7 to June 15, 2020. Notice to the Annual General Meeting will be published in a separate press release.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Ulf Richenberg, General Counsel, Karolinska Development AB

Phone: +46 70 29 860 25, e-mail:

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

Attachment

EN
16/03/2020

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures AB (publ) carries out a directed issue of shares to guarant...

KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KDVENTURES AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO...

2h / 48m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures AB (publ) genomför riktad nyemission av aktier till garante...

KDventures AB (publ) genomför riktad nyemission av aktier till garanter i samband med den genomförda företrädesemissionen EJ AVSEDD FÖR DISTRIBUTION ELLER PUBLICERING, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, KANADA, JAPAN, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDKOREA, SYDAFRIKA ELLER INOM ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIGT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE OM, ELLER INBJUDAN TILL, ATT FÖRVÄRVA ELLER TECKNA NÅGRA VÄRDEPAPPER I KDVENTURES AB (PUBL) I NÅGON JURISDIKTION. SE ÄVEN AVSN...

2h / 48m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as...

KDventures´ portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine cand...

February 10, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

KDventures portföljbolag SVF Vaccines utser Raheleh Nassaji till verks...

KDventures portföljbolag SVF Vaccines utser Raheleh Nassaji till verkställande direktör STOCKHOLM, 10 februari 2026. KDventures AB (Nasdaq Stockholm: KDV) meddelar idag att portföljbolaget SVF Vaccines har utsett Raheleh Nassaji till vd. Hon kommer att leda bolaget i transitionen av bolagets ledande vaccinkandidat SVF-001 till klinisk utveckling i fas 1. SVF Vaccines utvecklar DNA-vaccin och immunterapier baserat på en patenterad teknologi från Karolinska institutet. Inför initieringen av den första kliniska studien med bolagets ledande vaccinkandidat SVF-001, har SVF Vaccines utsett Rahel...

February 10, 2026 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development’s portfolio company SVF Vaccines and Novakand P...

Karolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand Pharma. Throughout the agreement, Novakand will acquire all shares in SVF Vaccines and pay with newly issued shares in Novakand, a transaction that corresponds to a value of around SEK 55 million. The transaction is conditional on, amongst other things, approval by an extraor...

February 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch